Collectively, this evidence points to a protective response, where the decrease in ENT2 expression in IBD patients may reflect enhanced adenosine accumulation and initiation of A2BAR signaling to alleviate intestinal epithelial damage and reduce barrier permeability [24]. This evidence concerns the gene SLC29A2 and inflammatory bowel disease.